When will retatrutide be available?
It is not approved yet. Its large final-stage study, TRIUMPH-1, reported results in May 2026. As of this site's latest review, the company was expected to ask the FDA for approval later in 2026. Two more TRIUMPH studies were still reporting. Until the FDA finishes its review and approves it, retatrutide is not a legal prescription drug. Any timeline beyond what has been stated publicly is a guess.
Studies in people from the compound pages this answer belongs to
- Retatrutide
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial 2023 PMID 37366315
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial 2024 PMID 38858523
- A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1) 2026 NCT05929066
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.